Fri Aug 4 16:36:35 2006
Complete replication of hepatitis C virus in cell culture
Lindenbach BD, Evans MJ, Syder AJ, et al.
SCIENCE 309 (5734): 623-626 JUL 22 2005
and the citing papers
stopwords, and 2-character and smaller words are excluded, Word count: 639, All words count: 954
Grand TLCS: 116, Grand TGCS: 195| View: Overview | Sorted by LCS. |
Page 1 of 2: [ 1 2 ]
| # | Word | Pubs | TLCS | TGCS
|
|---|
| 1 | HEPATITIS | 56 | 114 | 191
|
| 2 | VIRUS | 47 | 108 | 165
|
| 3 | REPLICATION | 12 | 83 | 95
|
| 4 | CELL | 10 | 78 | 79
|
| 5 | CULTURE | 4 | 76 | 77
|
| 6 | COMPLETE | 1 | 74 | 74
|
| 7 | FUNCTION | 2 | 7 | 15
|
| 8 | GENOME | 2 | 7 | 15
|
| 9 | INFECTIOUS | 7 | 7 | 9
|
| 10 | UNRAVELLING | 1 | 7 | 15
|
| 11 | ADAPTOR | 1 | 6 | 41
|
| 12 | ANTIVIRAL | 7 | 6 | 42
|
| 13 | CARDIF | 1 | 6 | 41
|
| 14 | PATHWAY | 1 | 6 | 41
|
| 15 | PROTEIN | 5 | 6 | 42
|
| 16 | RIG-I | 1 | 6 | 41
|
| 17 | TARGETED | 1 | 6 | 41
|
| 18 | ACTIVATION | 4 | 5 | 6
|
| 19 | ENTRY | 6 | 5 | 5
|
| 20 | CELLS | 8 | 4 | 4
|
| 21 | GLYCOPROTEINS | 2 | 4 | 5
|
| 22 | HEPATOMA | 4 | 4 | 4
|
| 23 | HUMAN | 8 | 4 | 4
|
| 24 | INTERFERON | 4 | 4 | 16
|
| 25 | LOW-PH-TRIGGERED | 1 | 4 | 4
|
| 26 | MECHANISM | 3 | 4 | 18
|
| 27 | PRODUCTION | 3 | 4 | 5
|
| 28 | RIBAVIRIN | 4 | 4 | 18
|
| 29 | TEMPERATURE-DEPENDENT | 1 | 4 | 4
|
| 30 | TIME-AND | 1 | 4 | 4
|
| # | Word | Pubs | TLCS | TGCS
|
|---|
| 31 | ACTION | 2 | 3 | 15
|
| 32 | FUSION | 2 | 3 | 3
|
| 33 | INTERACTIONS | 2 | 3 | 9
|
| 34 | LIPOSOMES | 1 | 3 | 3
|
| 35 | LOW | 1 | 3 | 3
|
| 36 | MEDIATE | 2 | 3 | 3
|
| 37 | MEMBRANE | 1 | 3 | 3
|
| 38 | PH-DEPENDENT | 1 | 3 | 3
|
| 39 | TREATMENT | 1 | 3 | 15
|
| 40 | UNSCRAMBLING | 1 | 3 | 9
|
| 41 | VIRUS-HOST | 1 | 3 | 9
|
| 42 | CDNA-TRANSFECTED | 1 | 2 | 2
|
| 43 | CULTURE-GROWN | 1 | 2 | 2
|
| 44 | HCV | 6 | 2 | 3
|
| 45 | INHIBITS | 3 | 2 | 3
|
| 46 | RECULTURED | 1 | 2 | 2
|
| 47 | ROBUST | 1 | 2 | 2
|
| 48 | STABLY | 1 | 2 | 2
|
| 49 | SYSTEM | 2 | 2 | 2
|
| 50 | VITRO | 2 | 2 | 2
|
| 51 | VIVO | 3 | 2 | 4
|
| 52 | ANALYSIS | 3 | 1 | 4
|
| 53 | ANTI-HEPATITIS | 1 | 1 | 1
|
| 54 | APOPTOSIS | 1 | 1 | 2
|
| 55 | ASSEMBLY | 2 | 1 | 2
|
| 56 | CIRCLE | 1 | 1 | 2
|
| 57 | COMPLEX | 1 | 1 | 4
|
| 58 | CONCOMITANT | 1 | 1 | 2
|
| 59 | CULTURED | 1 | 1 | 1
|
| 60 | DETECTION | 1 | 1 | 1
|
| # | Word | Pubs | TLCS | TGCS
|
|---|
| 61 | DISORDERS | 2 | 1 | 2
|
| 62 | EFFECTS | 3 | 1 | 3
|
| 63 | EFFICIENTLY | 1 | 1 | 1
|
| 64 | FEATURES | 1 | 1 | 1
|
| 65 | FULL | 1 | 1 | 2
|
| 66 | FUNCTIONAL | 2 | 1 | 2
|
| 67 | GENOTYPE | 1 | 1 | 1
|
| 68 | HIGHLY | 1 | 1 | 1
|
| 69 | HUTCHINSON | 1 | 1 | 1
|
| 70 | INCORPORATION | 1 | 1 | 2
|
| 71 | INHIBITOR | 5 | 1 | 1
|
| 72 | INTRACELLULARLY | 1 | 1 | 2
|
| 73 | LIPOPROTEIN | 2 | 1 | 1
|
| 74 | LOCALIZATION | 1 | 1 | 1
|
| 75 | LOW-DENSITY | 1 | 1 | 1
|
| 76 | LYMPHOCYTE | 1 | 1 | 2
|
| 77 | LYMPHOCYTES | 1 | 1 | 2
|
| 78 | MOLECULAR | 3 | 1 | 1
|
| 79 | NAIVE | 1 | 1 | 2
|
| 80 | NOVEL | 4 | 1 | 1
|
| 81 | OCCURS | 1 | 1 | 2
|
| 82 | OXIDIZED | 1 | 1 | 1
|
| 83 | PATHOGENETIC | 1 | 1 | 2
|
| 84 | PESTIVIRUS | 1 | 1 | 1
|
| 85 | POLYMERASE | 2 | 1 | 1
|
| 86 | PROSPECTS | 1 | 1 | 6
|
| 87 | PROTEINS | 3 | 1 | 1
|
| 88 | PSEUDOPARTICLES | 1 | 1 | 2
|
| 89 | QUANTITATIVE | 2 | 1 | 4
|
| 90 | RECOMBINANT | 2 | 1 | 2
|
| # | Word | Pubs | TLCS | TGCS
|
|---|
| 91 | REPLICATES | 1 | 1 | 1
|
| 92 | REPLICON | 4 | 1 | 1
|
| 93 | REQUIRES | 1 | 1 | 2
|
| 94 | REVEALED | 1 | 1 | 1
|
| 95 | RNA | 9 | 1 | 2
|
| 96 | RNA-DEPENDENT | 1 | 1 | 1
|
| 97 | SALIENT | 1 | 1 | 1
|
| 98 | SELECTIVE | 1 | 1 | 1
|
| 99 | SENSITIVE | 1 | 1 | 1
|
| 100 | STRAIN | 2 | 1 | 1
|
| 101 | STRUCTURAL | 1 | 1 | 1
|
| 102 | SUBCELLULAR | 1 | 1 | 1
|
| 103 | TARGETS | 2 | 1 | 1
|
| 104 | TISSUE | 1 | 1 | 2
|
| 105 | VACCINE | 1 | 1 | 6
|
| 106 | VIRAL | 5 | 1 | 1
|
| 107 | VIRUS-ASSOCIATED | 1 | 1 | 2
|
| 108 | ABUSE | 1 | 0 | 0
|
| 109 | ACHILLES | 1 | 0 | 0
|
| 110 | ACRIDONES | 1 | 0 | 0
|
| 111 | ACTIVITIES | 1 | 0 | 0
|
| 112 | ACTIVITY | 3 | 0 | 0
|
| 113 | ADAPTIVE | 1 | 0 | 0
|
| 114 | ADVANCES | 1 | 0 | 1
|
| 115 | AGENTS | 1 | 0 | 0
|
| 116 | ALPHA | 1 | 0 | 0
|
| 117 | ALPHA-GLUCOSIDASE | 1 | 0 | 0
|
| 118 | ANALYSES | 1 | 0 | 0
|
| 119 | ANTI-BVDV | 1 | 0 | 0
|
| 120 | ANTI-HCV | 1 | 0 | 0
|
| # | Word | Pubs | TLCS | TGCS
|
|---|
| 121 | ANTIBODIES | 1 | 0 | 0
|
| 122 | ANTIBODY | 1 | 0 | 0
|
| 123 | APOB-CONTAINING | 1 | 0 | 0
|
| 124 | APOLIPOPROTEIN | 1 | 0 | 0
|
| 125 | APPROACH | 1 | 0 | 0
|
| 126 | APPROACHES | 1 | 0 | 0
|
| 127 | ASSAY | 1 | 0 | 0
|
| 128 | BACULOVIRUS | 1 | 0 | 0
|
| 129 | BILIARY | 1 | 0 | 0
|
| 130 | BINDING | 2 | 0 | 0
|
| 131 | BIOLOGICAL | 2 | 0 | 1
|
| 132 | BROADLY | 1 | 0 | 0
|
| 133 | CAPTURING | 1 | 0 | 0
|
| 134 | CARCINOMA | 1 | 0 | 0
|
| 135 | CELL-CELL | 1 | 0 | 0
|
| 136 | CHARACTERIZATION | 4 | 0 | 0
|
| 137 | CHIMERAS | 1 | 0 | 0
|
| 138 | CHRONIC | 1 | 0 | 0
|
| 139 | CLA | 1 | 0 | 0
|
| 140 | CLATHRIN-MEDIATED | 1 | 0 | 0
|
| 141 | CLEAVAGE | 2 | 0 | 0
|
| 142 | CLINICAL | 1 | 0 | 1
|
| 143 | COMBINATION | 1 | 0 | 0
|
| 144 | CONFLUENCE-BASED | 1 | 0 | 1
|
| 145 | CONSTRUCTION | 1 | 0 | 0
|
| 146 | CORE | 1 | 0 | 0
|
| 147 | CORE-RNA | 1 | 0 | 0
|
| 148 | COUNTERS | 1 | 0 | 2
|
| 149 | CULTURES | 1 | 0 | 0
|
| 150 | CYCLOSPORIN | 1 | 0 | 0
|
| # | Word | Pubs | TLCS | TGCS
|
|---|
| 151 | CYCLOSPORINE | 1 | 0 | 0
|
| 152 | CYTOSKELETON | 1 | 0 | 0
|
| 153 | DC-SIGN | 1 | 0 | 0
|
| 154 | DC-SIGNR | 1 | 0 | 0
|
| 155 | DEBIO | 1 | 0 | 0
|
| 156 | DEFINED | 1 | 0 | 0
|
| 157 | DELETION | 1 | 0 | 0
|
| 158 | DENSITY | 1 | 0 | 0
|
| 159 | DEPENDS | 1 | 0 | 0
|
| 160 | DEVELOPMENT | 1 | 0 | 1
|
| 161 | DIFFERENT | 2 | 0 | 0
|
| 162 | DIHYDROXY-4-CARBOXYPYRIMIDINES | 1 | 0 | 0
|
| 163 | DIMERIZATION | 1 | 0 | 0
|
| 164 | DIRECT | 1 | 0 | 0
|
| 165 | DISCOVERY | 2 | 0 | 0
|
| 166 | DISPENSABLE | 1 | 0 | 0
|
| 167 | DISTINCT | 3 | 0 | 0
|
| 168 | DIVERSE | 1 | 0 | 0
|
| 169 | DOMAINS | 1 | 0 | 0
|
| 170 | DRUG | 1 | 0 | 1
|
| 171 | DSRNA-INDUCED | 1 | 0 | 0
|
| 172 | EARLY | 1 | 0 | 0
|
| 173 | EFFECT | 3 | 0 | 1
|
| 174 | EMPIRICISM | 1 | 0 | 0
|
| 175 | ENDOCYTOSIS | 1 | 0 | 0
|
| 176 | ENDOTHELIAL | 1 | 0 | 0
|
| 177 | ENDOTHELIUM | 1 | 0 | 0
|
| 178 | ENGAGEMENT | 1 | 0 | 0
|
| 179 | ENHANCES | 1 | 0 | 0
|
| 180 | ENVELOPE | 1 | 0 | 0
|
| # | Word | Pubs | TLCS | TGCS
|
|---|
| 181 | EPITOPE | 1 | 0 | 0
|
| 182 | ERADICATION | 1 | 0 | 0
|
| 183 | ESCAPE | 1 | 0 | 0
|
| 184 | EXHIBITS | 1 | 0 | 0
|
| 185 | EXPRESSION | 4 | 0 | 1
|
| 186 | FACE | 1 | 0 | 1
|
| 187 | FULLY | 1 | 0 | 0
|
| 188 | FUNCTIONS | 1 | 0 | 0
|
| 189 | FUTURE | 1 | 0 | 1
|
| 190 | GENERATED | 1 | 0 | 0
|
| 191 | GENERATION | 1 | 0 | 0
|
| 192 | GROW | 1 | 0 | 0
|
| 193 | GROWTH | 1 | 0 | 1
|
| 194 | HAIRPIN | 1 | 0 | 0
|
| 195 | HCV-LIKE | 2 | 0 | 0
|
| 196 | HEEL | 1 | 0 | 0
|
| 197 | HELICASES | 1 | 0 | 0
|
| 198 | HEPATOCELLULAR | 1 | 0 | 0
|
| 199 | HEPATOCYTES | 2 | 0 | 0
|
| 200 | HIGH | 1 | 0 | 0
|
Page 1 of 2: [ 1 2 ]